2025
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients
de Andrea C, Abengozar-Muela M, Arranz J, Climent M, Puente J, Vizcay Á, de la Fuente L, Jurado J, Bonfill T, Santander C, Villa J, Pujol E, Rosero A, Gomez J, Fernández E, Fernández C, Ramirez I, Arnáiz P, López-Janeiro Á, Melero I, Sanmamed M, Pérez-Gracia J. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. OncoImmunology 2025, 14: 2538687. PMID: 40778981, DOI: 10.1080/2162402x.2025.2538687.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, CDBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHepatitis A Virus Cellular Receptor 2HumansLymphocyte Activation Gene 3 ProteinMaleMiddle AgedProgrammed Cell Death 1 ReceptorTumor MicroenvironmentUrinary Bladder NeoplasmsConceptsAdvanced urothelial cancerMultiplexed quantitative immunofluorescenceTumor microenvironmentT cellsClinical efficacyPD-1LAG-3Tim-3Urothelial cancerPredictive biomarkersReal-world evidenceDistribution of CD8+ T cellsQuantitative immunofluorescenceCD8+ T-cell densityAdvanced urothelial carcinoma patientsAssociation of PD-1Intratumoral CD8 T cellsPatients treated with atezolizumabPre-treatment tumor samplesCD8+ T cellsPD-1/PD-L1 pathwayHundred-nine patientsPD-L1 blockadeResponse to atezolizumabCD8 T cellsProteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer
Holt M, Dou Y, Young M, Saltzman A, Anurag M, Lei J, Jain A, Leng M, Kim B, Dobrolecki L, Faucher S, Savage S, Wang C, Shi Z, Villanueva H, Kremers K, Drinnon K, Castro P, Ittmann M, Khatani M, Kim S, Ellis M, Zhang B, Malovannaya A, Lerner S. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Reports Medicine 2025, 6: 102255. PMID: 40749681, PMCID: PMC12432383, DOI: 10.1016/j.xcrm.2025.102255.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerIsoform-level analysisBladder cancerMulti-omics clusteringBenefit of combination therapyFamily proteinsPhosphoproteomic dataBiomarkers of chemosensitivityProteogenomic characterizationJAK/STAT pathwayProtein abundanceAssociated with chemoresistanceWnt signalingPD-L1ProteinCombination therapyChemoresistance mechanismsMolecular subtypesChemotherapy sensitivityChemoresistanceTherapeutic opportunitiesATAD1SubtypesGenomeCancerInternational multicenter study of stereotactic radiosurgery for bladder cancer brain metastases
Perron R, Iorio-Morin C, Chytka T, Simonova G, Chiang V, Singh C, Niranjan A, Wei Z, Lunsford L, Peker S, Samanci Y, Peterson J, Ross R, Rusthoven C, Lee C, Yang H, Yener U, Sheehan J, Kondziolka D, Mathieu D. International multicenter study of stereotactic radiosurgery for bladder cancer brain metastases. Journal Of Neuro-Oncology 2025, 174: 235-241. PMID: 40249513, DOI: 10.1007/s11060-025-05039-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedRadiosurgeryRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsCancer brain metastasesInternational Radiosurgery Research FoundationStereotactic radiosurgeryBrain metastasesBrain metastases treated with stereotactic radiosurgeryFollow-upStudy of stereotactic radiosurgeryTime of stereotactic radiosurgeryEvaluate stereotactic radiosurgeryFractionated stereotactic radiosurgeryMedian marginal doseNon-urothelial histologyBrain metastasis diagnosisAdverse radiation effectsImaging follow-upInternational multicenter studyMarginal doseResults103 patientsMedian KPSTumor controlSystemic metastasesLeptomeningeal disseminationMedian survivalSurgical resectionCorticosteroid intakeComparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma
Jaime-Casas S, Chawla N, Salgia N, Mercier B, Govindarajan A, Li X, Castro D, Ebrahimi H, Barragan-Carrillo R, Zang P, LeVee A, Zugman M, Dizman N, Hsu J, Meza L, Zengin Z, Chehrazi-Raffle A, Dorff T, Pal S, Tripathi A. Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma. JCO Precision Oncology 2025, 9: e2400947. PMID: 40209138, DOI: 10.1200/po-24-00947.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Small CellCarcinoma, Transitional CellFemaleGenomicsHumansLung NeoplasmsMaleMiddle AgedMutationSmall Cell Lung CarcinomaUrinary Bladder NeoplasmsConceptsSmall cell bladder cancerSmall cell lung cancerUrothelial carcinomaGenomic alterationsBladder cancerSmall cell lung cancer patientsSmall cell lung carcinomaSmall cell carcinomaRare histologic variantCell lung carcinomaAggressive disease courseCell lung cancerPathogenic genomic alterationsImproving clinical outcomesTreated with approachesHistological variantsCell carcinomaHistological groupsLung carcinomaClinical outcomesPoor outcomeRetrospective natureDisease courseLung cancerGenomic profilingAvelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients ☆
Gupta S, Duran M, Sridhar S, Powles T, Bellmunt J, Park S, Gurney H, Tsuchiya N, Petrylak D, Tomita Y, di Pietro A, Manitz J, Tyroller K, Hoffman J, Jacob N, Grivas P. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients ☆. ESMO Open 2025, 10: 104506. PMID: 40107155, PMCID: PMC11964637, DOI: 10.1016/j.esmoop.2025.104506.Peer-Reviewed Original ResearchConceptsProgression-free survivalPlatinum-based chemotherapyOverall survivalUrothelial carcinomaProgression-free survival analysisOlder ageAdvanced urothelial carcinomaFirst-line maintenanceMetastatic urothelial carcinomaProlonged overall survivalPhase III trialsKaplan-Meier methodQuality-adjusted timeLong-term outcomesJAVELIN BladderMedian OSIII trialsFirst-linePrimary endpointAvelumabBladder cancerOlder patientsAge subgroupsSupportive carePatients
2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBCG-unresponsive NMIBCBacillus Calmette-GuerinOncological outcomesBladder cancerIntravesical gemcitabineNon-muscle invasive bladder cancerBacillus Calmette-Guerin treatmentHazard ratioBacillus Calmette-Guerin therapyBacillus Calmette-Guerin groupCompare oncologic outcomesInvasive bladder cancerCox proportional hazard ratiosKaplan-Meier methodNoninvasive bladder cancerRates of PFSProportional hazard ratiosAssociated with lower ratesFood and Drug Administration guidelinesBCG-unresponsiveDrug Administration guidelinesGemcitabine-docetaxelBCG therapyProgression-FreeDNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precision Oncology 2024, 8: e2400287. PMID: 39499893, PMCID: PMC12088707, DOI: 10.1200/po.24.00287.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCisplatinDNA DamageFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessUrinary Bladder NeoplasmsXeroderma Pigmentosum Group D ProteinConceptsNeoadjuvant cisplatin-based chemotherapyMuscle-invasive bladder cancerProgression-free survivalDDR alterationsDNA damage response alterationPathological responseBladder cancerDNA damage responseAssociated with pathological responseNeoadjuvant chemotherapy sensitivityPretreatment tumor specimensPathological response rateCisplatin-based chemotherapyDNA damage response genesEstimates of hazard ratiosOverall survivalRadical cystectomyTumor specimensPerformance statusClinical stageChemotherapy sensitivityCox regressionHazard ratioNext-generation sequencingPatientsMitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer
Reddy K, Piyarathna D, Park J, Putluri V, Amara C, Kamal A, Xu J, Kraushaar D, Huang S, Jung S, Eberlin L, Johnson J, Kittles R, Ballester L, Parsawar K, Siddiqui M, Gao J, Gramer A, Bollag R, Terris M, Lotan Y, Creighton C, Lerner S, Sreekumar A, Kaipparettu B, Putluri N. Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight 2024, 9: e172336. PMID: 39253977, PMCID: PMC11385078, DOI: 10.1172/jci.insight.172336.Peer-Reviewed Original ResearchConceptsBladder cancerOxidative phosphorylationComponents of complex IComplex IElevated mitochondrial oxidative phosphorylationComprehensive RNA-seqReduced basal respirationActive oxidative phosphorylationMitochondrial oxidative phosphorylationDecreased tumor growthTumor growth potentialIncreased disease progressionMitochondrial respiration rateAfrican American patientsRNA-seqRace-specific differencesMitochondrial reprogrammingEuropean AmericansMetabolic rewiringOXPHOS activityBasal respirationGlutamine metabolismGLS1 expressionPreclinical studiesATP productionHypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma
Yang Z, Chen Q, Dong S, Xu P, Zheng W, Mao Z, Qian C, Zheng X, Dai L, Wang C, Shi H, Li J, Yuan J, Yu W, Xu C. Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma. Journal Of Translational Medicine 2024, 22: 608. PMID: 38956589, PMCID: PMC11218302, DOI: 10.1186/s12967-024-05420-3.Peer-Reviewed Original ResearchConceptsRecurrence monitoringMethodsThe methylation levelsIndicator of recurrenceBackgroundUrothelial carcinomaClinical recurrenceUrothelial carcinomaBenign diseaseUrological malignanciesPostoperative surveillanceUC diagnosisUC patientsTraining cohortUrothelial markersValidation cohortRecurrenceClinical scenariosUrinary systemClinical utilityCarcinomaMethylation markersPatientsUrine samplesTissue samplesUrineDiagnosisImpact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Skelton W, Masur J, Thomas J, Fallah P, Jain R, Ravi P, Mantia C, McGregor B, Nuzzo P, Adib E, Zarif T, Preston M, Clinton T, Li R, Steele G, Kassouf W, Freeman D, Pond G, Jain R, Sonpavde G. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102143. PMID: 39032202, DOI: 10.1016/j.clgc.2024.102143.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerPathological complete responsePathologic complete response rateRenin-angiotensin systemNeoadjuvant chemotherapyAngiotensin-converting enzyme inhibitorsConverting Enzyme InhibitorsOverall survivalRadical cystectomyPerformance statusClinical stageComplete responseBladder cancerAssociated with increased pCRAssociated with pathologic complete responseFemale sexAssociated with improved OSImpact of angiotensin-converting enzyme inhibitorsCycles of neoadjuvant chemotherapyMuscle invasive bladder cancerClinical stage of diseaseEnzyme inhibitorsAssociated with OSInitiation of therapyInvasive bladder cancerEfficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, Bivalacqua T, Montgomery J, Lerner S, Busby J, Poch M, Crispen P, Steinberg G, Schuckman A, Downs T, Mashni J, Lane B, Guzzo T, Bratslavsky G, Karsh L, Woods M, Brown G, Canter D, Luchey A, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Sankin A, O’Donnell M, Sawutz D, Philipson R, Parker N, Yla-Herttuala S, Rehm D, Jakobsen J, Juul K, Dinney C. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. Journal Of Urology 2024, 212: 74-86. PMID: 38704840, DOI: 10.1097/ju.0000000000004020.Peer-Reviewed Original ResearchConceptsNonmuscle-invasive bladder cancerPhase 3 trialBladder cancerFollow-upAdenoviral vector-based gene therapyProgression to muscle-invasive diseaseOpen-label phase 3 trialVector-based gene therapyCystectomy-free survivalMuscle-invasive diseaseMedian Follow-UpCarcinoma in situBladder preservationNadofaragene firadenovecOverall survivalGene therapyCytological assessmentTa/T1PatientsUS sitesCohortReceiving treatmentMonthsCancerHGRFC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorC-Reactive ProteinCarcinoma, Transitional CellHumansPrognosisUrinary Bladder NeoplasmsUrologic NeoplasmsConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatientsScoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
Rüschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, Martini M, Cheng L, Tretiakova M, Mitchell C, Anders R, Robert M, Fahy D, Pyle M, Le Q, Yu L, Glass B, Baxi V, Babadjanova Z, Pratt J, Brutus S, Karasarides M, Hartmann A. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Virchows Archiv 2024, 484: 597-608. PMID: 38570364, DOI: 10.1007/s00428-024-03795-8.Peer-Reviewed Original ResearchConceptsPD-L1 expressionImmune checkpoint inhibitorsPD-L1Tumor cellsAssess programmed death ligand 1Assessment of PD-L1 expressionScoring of PD-L1 expressionInternational multi-institutional studyPD-L1 expression analysisFood and Drug Administration-approvedPD-L1 stainingDeath-ligand 1Drug Administration-approvedMulti-institutional studyCheckpoint inhibitorsUrothelial carcinomaPathological assessmentBiomarker expressionInterobserver variabilityLigand 1Cancer treatmentExpert pathologistsClinical settingMultinational studyPositive rate‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder
Myers A, Tan W, de Groot J, Westney O, Kamat A. ‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU International 2024, 134: 45-47. PMID: 38379218, DOI: 10.1111/bju.16302.Peer-Reviewed Original ResearchThe IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer
Amara C, Kami Reddy K, Yuntao Y, Chan Y, Piyarathna D, Dobrolecki L, Shih D, Shi Z, Xu J, Huang S, Ellis M, Apolo A, Ballester L, Gao J, Hansel D, Lotan Y, Hodges H, Lerner S, Creighton C, Sreekumar A, Zheng W, Msaouel P, Kavuri S, Putluri N. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nature Communications 2024, 15: 1373. PMID: 38355560, PMCID: PMC10867091, DOI: 10.1038/s41467-024-45132-2.Peer-Reviewed Original ResearchMeSH KeywordsCell Line, TumorHumansInterleukin-6Signal TransductionSMARCB1 ProteinSTAT3 Transcription FactorUrinary Bladder NeoplasmsConceptsSignaling AxisSMARCB1-deficient tumorsSMARCB1 deficiencyBladder cancerChromatin accessibilitySTAT3 inhibitorTumor growthSMARCB1 lossPatient-derived xenograft modelsCell line-derived xenograftsTherapeutic vulnerabilitiesTarget pathwaysReduced tumor growthIncreased tumor growthCell linesIn vivo modelsSTAT3Gene signatureSMARCB1TTI-101Solid tumorsXenograft modelClinical evaluationDisease progressionTumor
2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studiesPeripheral Blasts in a Patient Receiving Chemotherapy
Kshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinGemcitabineGranulocyte Colony-Stimulating FactorHumansLeukopoiesisUrinary Bladder NeoplasmsPhase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Petrylak D, Eigl B, George S, Heath E, Hotte S, Chism D, Nabell L, Picus J, Cheng S, Appleman L, Sonpavde G, Morgans A, Pourhosseini P, Wu R, Standley L, Croitoru R, Yu E. Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research 2023, 30: of1-of11. PMID: 37861407, PMCID: PMC10767306, DOI: 10.1158/1078-0432.ccr-22-3627.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, Transitional CellHumansImmunoconjugatesUrinary Bladder NeoplasmsConceptsMetastatic urothelial carcinomaObjective response rateDose-limiting toxicityAntibody-drug conjugatesUrothelial carcinomaCommon treatment-emergent adverse eventsInvestigational antibody-drug conjugateTreatment-emergent adverse eventsI dose-escalation studyDose-expansion cohortsCheckpoint inhibitor therapyPhase II doseDose-escalation studyDose-proportional mannerMultiple-dose administrationBest overall responseMonomethyl auristatin ECytotoxic drug monomethyl auristatin EPrior chemotherapyAdverse eventsDose escalationInhibitor therapyPeripheral neuropathyOcular toxicityExpansion trialEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak D. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆. Annals Of Oncology 2023, 34: 1047-1054. PMID: 37678672, DOI: 10.1016/j.annonc.2023.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCarcinoma, Transitional CellDocetaxelHumansUrinary Bladder NeoplasmsConceptsProgression-free survivalEnfortumab vedotinAdverse eventsUrothelial carcinomaTreatment-related adverse event ratesMeaningful overall survival benefitPrior platinum-containing chemotherapyWhite blood cell countEvent ratesAdvanced urothelial carcinomaMetastatic urothelial carcinomaOverall survival benefitPeripheral sensory neuropathyPlatinum-containing chemotherapyNew safety signalsPhase III trialsAdverse event ratesRisk of deathBlood cell countIII trialsMaculopapular rashNeutrophil countObjective responseOverall survivalSurvival benefitOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBCG VaccineCystectomyHumansNon-Muscle Invasive Bladder NeoplasmsUrinary BladderUrinary Bladder NeoplasmsUrologyConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian Follow-UpInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removal
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply